Zobrazeno 1 - 10
of 66
pro vyhledávání: '"John A Pieper"'
Autor:
Arijana Meštrović, Asmaa Al-Haqan, Marwan El-Akel, Naoko Arakawa, Banan Abdulrzaq S. Mukhalati, Lina Bader, Ian Bates, Andreia Bruno-Tomé, Filipa Alves da Costa, Mariet Eksteen, Paul John Gallagher, Kat Hall, Martin C. Henman, Dai John, Donald E. Mager, John A. Pieper, Michael Rouse, Anisha Kaur Sandhu, Carl R. Schneider, Toyin Tofade, Catherine Duggan
Publikováno v:
Pharmacy Education. 22:100-109
The FIP (International Pharmaceutical Federation) Global Competency Framework for Educators and Trainers in Pharmacy (FIP-GCFE) is an ongoing project of the Academic Pharmacy Section of FIP in cooperation and collaboration with Sections, Special Inte
Autor:
John Albert Pieper
Publikováno v:
Pharmacy Education. 22:19-23
Strategic planning is a vital and ongoing process to define an organisation’s purpose (mission, vision, and values), the direction an organisation is going in the future and how an organisation will arrive at a desired future state (goals and objec
Autor:
Matthew J. Triebe, Sidi Deng, Jesús R. Pérez-Cardona, Byung Gun Joung, Haiyue Wu, Neha Shakelly, John P. Pieper, Xiaoyu Zhou, Thomas Maani, Fu Zhao, John W. Sutherland
Publikováno v:
Green Manufacturing Open. 1:10
With the increasing concern due to climate change caused by a higher atmospheric concentration of CO2 and other greenhouse gases, reducing environmental impact is becoming more important for every part of society. Manufacturing is responsible for a s
Autor:
William D. Figg, Patricia D. Kroboth, Marilyn K. Speedie, Howard L. McLeod, Daren L. Knoell, Palmer Taylor, Richard T. Okita, Cindy H. Chau, Jordan L. Cohen, Mary Anne Koda-Kimble, Robert A. Blouin, Michael D. Reed, Peter C. Preusch, Timothy S. Tracy, Kenneth W. Miller, Kathy Giacomini, John A. Pieper
Publikováno v:
Pharmacotherapy. 28:821-833
To address the shortage of research-trained pharmaceutical scientists (or doctor of pharmacy [Pharm.D.] scientists), a 2-day pharmacy research conference titled "Pharm.D. Pathways to Biomedical Research" was convened on December 13-14, 2006, at the N
Autor:
Melanie S. Joy, Cynthia J. Denu-Ciocca, Susan L. Hogan, Kimberly A Dornbrook-Lavender, Hyunsook Chin, John A. Pieper
Publikováno v:
Pharmacotherapy. 25:335-344
Study Objectives. To determine the effects of atorvastatin on low-density lipoprotein cholesterol (LDL) particle size and C-reactive protein (CRP) concentrations in patients undergoing long-term hemodialysis. Another objective was to compare the effe
Autor:
John A. Pieper, Kevin P. O’Reilly, Chad E. Huggins, Anna M. Wodlinger, Gail Tudor, E. Magnus Ohman, Cynthia J. Denu-Ciocca, Malay Agrawal, George A. Stouffer
Publikováno v:
Heart Drug. 4:87-91
Background: Prior studies have produced conflicting results on whether N-acetylcysteine (NAC) reduces the incidence of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CA). The dosing regimens of NAC in these studies se
Autor:
John A. Pieper
Publikováno v:
American Journal of Health-System Pharmacy. 60:S9-S14
The pharmacokinetics, efficacy, and safety of niacin and its various formulations are discussed. Niacin has been used for decades for the treatment of dyslipidemia because of its favorable effects on all lipoprotein parameters. Niacin significantly i
Publikováno v:
Pharmacotherapy. 23:720-725
Study Objective. To determine if differences in the pharmacokinetics of losartan and its pharmacologically active E3174 metabolite exist among individuals expressing the cytochrome P450 (CYP) 2C9*1/*1, *1/*2, and *1/*3 genotypes. Design. Single-dose
Autor:
John A. Pieper, Anna M. Wodlinger
Publikováno v:
Pharmacotherapy. 23:57-63
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with thromboembolic events and hemodynamic impairment that results in considerable morbidity, mortality, and cost. Cardioversion to sinus rhythm is a common approac
Publikováno v:
Cardiovascular Drugs and Therapy. 17:75-82
Current strategies for both the primary and secondary prevention of coronary heart disease (CHD) focus on the traditional risk factors, such as hypertension, smoking cessation, and cholesterol, as the primary determinants of the cardiac risk profile,